Takara Bio Chinese Subsidiary to Expand Lines of Business, Files Chinese Clinical Trial Application.Tokyo, Japan, Mar 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takara Bio announced on March 28 that its subsidiary, Takara Biomedical Technology Biomedical technology involves the application of engineering and technology principles to the domain of living or biological systems. Usually biomedical denotes a greater stress on problems related to human health and diseases. (Beijing), has received approval from the Chinese Ministry of Commerce for an expansion of its lines of business, namely the import and wholesaling of reagents for biological research and laboratory equipment. With this approval, the subsidiary will begin importing and wholesaling products offered by two other Takara Bio subsidiaries, Takara Biotechnology (Dailian) and Clontech, on April 1. Takara Bio also plans to export bio-related products manufactured in China. At the same time, Takara Bio and Takara Biomedical Technology, filed a clinical trial application with the Chinese State Food and Drug Administration The State Food and Drug Administration (SFDA Simplified Chinese: 国家食品药品监督管理局) is founded on the basis of the State Drug Administration. in collaboration with the Chinese Academy of Medical Sciences. Going forward, the three partners plan to proceed with studies on cellular immunotherapy Immunotherapy The treatment of cancer by improving the ability of a tumor-bearing individual (the host) to reject the tumor immunologically. There are molecules on the surface of tumor cells, and perhaps in their interior, that are recognized as different from targeted at renal cancer. Specifically, the joint studies will focus on the activation of T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. using RetroNectin, Takara Bio's proprietary recombinant human fibronectin fragment. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion